<DOC>
	<DOCNO>NCT02437656</DOCNO>
	<brief_summary>Metformin oral antidiabetic biguanide class derive galega officinalis . Historical cohort patient diabetes show diabetic Metformin good chance survival diabetic Metformin . These observation lead vitro study metformin cancer cell . It thus demonstrate Metformin anti-proliferative property . The aim study evaluate efficacy metformin combination neoadjuvant radiochemotherapy treatment locally advanced rectal cancer .</brief_summary>
	<brief_title>Combination Metformin Neoadjuvant Radiochemotherapy Treatment Locally Advanced Rectal Cancer ( METCAP ) .</brief_title>
	<detailed_description>Patients eligible trial sign consent participate undergo dosimetric scan baseline . 48 hour later ( minimum ) , Metformin therapy start dosage 850 mg 2 time / day ( = 1700 mg / day ) . Seven day later ( minimum ) 48 hour surgery , dosage Metformin increase 850 mg 3 time / day ( = 2550 mg / day ) . This day ( J10 ) , patient start radiochemotherapy . For 5 week , 5 day 7 , patient receive 800 mg/m² Capecitabine 2 time / day ( morning evening ) ( = 1600 mg / m² / day ) 3D irradiation Intensity-Modulated Radiation Therapy ( IMRT ) total dose 50 Gy ( 5 session 2 Gy per week ) . 6 8 week completion chemoradiotherapy , surgery schedule . It consist tumor resection total resection meso rectum . Prior start treatment , patient clinical paraclinical examination undergo laboratory examination . Once week radiochemotherapy , patient clinical examination undergo laboratory examination . Three week end radiochemotherapy , patient clinical examination . Before surgery , patient clinical paraclinical examination . Finally , end study , patient clinical examination .</detailed_description>
	<mesh_term>Rectal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patient adenocarcinoma low middle rectum . 2 . T3 T4 stage ( T evaluate MRI / echoendoscopy ) . 3 . Absence distant metastasis . 4 . Patient require radiochemotherapy . 5 . Correct hematological condition : Neutrophils ≥ 1500 G / L , platelets ≥ 100 000 G / L. 6 . Age ≥ 18 year 7 . Performance status ( WHO ) ≤ 2 8 . Lactatemia ≤ Higher standard sample laboratory . 9 . For woman childbearing age , contraceptive method mandatory entire duration study . 1 . Other histology squamous cell carcinoma , neuroendocrine tumor , melanoma , etc . 2 . History lactic acidosis . 3 . Any diabetes ( According WHO definition : fasting plasma glucose ( FPG ) &gt; 1.26 g / L1 ) . 4 . Ongoing antidiabetic treatment Biguanides , hypoglycemic sulfamides , glinides , GLP1 analogue , gliptins , alphaglucosidase inhibitor Insulin insulin analogues 5 . Hypersensitivity capecitabine excipients fluorouracil . 6 . History severe unexpected reaction fluoropyrimidine therapy . 7 . Patient known deficiency dihydropyrimidine dehydrogenase ( DPD ) . 8 . Hypersensitivity metformin excipients . 9 . Renal failure impair renal function ( creatinine clearance &lt; 60 ml / min ) . 10 . Severe infection . 11 . Acute chronic disease may cause tissue hypoxia heart respiratory failure recent myocardial infarction ( &lt; 6 month ) . 12 . Hepatic insufficiency , acute alcohol intoxication , alcoholism . 13 . Psychiatric inability give consent . 14 . Contraindication radiation therapy and/or chemotherapy . 15 . Treatment sorivudine chemically related analogue , brivudine . 16 . Patient tutorship guardianship . 17 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Radiochemotherapy</keyword>
	<keyword>Metformin</keyword>
	<keyword>Rectal cancer</keyword>
</DOC>